Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos (NYSE: GKOS) announced that its Phase 4 trial of iDose TR with cataract surgery met the primary efficacy endpoint.
The randomized, controlled GLK-101-04 trial compared the combination with cataract surgery alone in adults with open-angle glaucoma or ocular hypertension. At month 3, mean diurnal intraocular pressure (IOP), or eye pressure measured across the day, fell 11.1 mmHg from baseline with the combination versus 7.4 mmHg with surgery alone. The reported incremental treatment effect was 3.6 mmHg (p<0.0001), demonstrating statistically significant superiority. All pre-specified secondary responder analyses also showed statistically significant superiority.
Through 3 months, there were no treatment-related adverse events of corneal endothelial cell loss or cystoid macular edema, and no serious corneal adverse events.
Glaukos (GKOS) entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104 for several retinal diseases.
The agreement covers neovascular age-related macular degeneration, diabetic macula edema, diabetic retinopathy and retinal vein occlusion. It also grants exclusive rights to the RevMod platform for discovery and development of up to four additional retinal biologic candidates in those diseases and geographic atrophy. RO-104 is designed to block VEGF-A, VEGF-C and Ang-2, pathways involved in vascular disease progression. Glaukos reports that RO-104 demonstrated superior preclinical efficacy versus approved anti-VEGF therapies in established animal models.
Glaukos (GKOS) announced three-year results from a Phase 3 extension study evaluating Epioxa treatment durability, vision and safety in keratoconus.
The GLK-202-03 study followed patients treated in the second pivotal Phase 3 trial after a single treatment, with no additional intervention during the extension period. Treated eyes sustained a 1.9-diopter improvement from baseline in maximum corneal curvature, a measure of corneal shape. At year 3, 29% of eyes gained at least two lines of best-corrected visual acuity, and 20% gained at least three lines. No serious adverse events, treatment-related adverse events or discontinuations due to adverse events were reported through three years. The extension included 38 eyes from 35 subjects, with 92% of eyes completing the year 3 visit. Glaukos said the findings support Epioxa's potential for long-term disease stabilization.
Glaukos (GKOS) plans to release its third quarter 2026 financial results after market close on October 28, 2026. Management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) that day. A webcast replay will be archived on the company’s website after the call.
Glaukos (GKOS) launched the “Could it be KC?” disease awareness campaign with NBA champion Stephen Curry to improve recognition and earlier detection of keratoconus, a rare progressive corneal disease that is often undiagnosed and untreated.
The campaign, beginning now with expanded activities planned in 2027, targets individuals, families, caregivers, and healthcare providers with information on warning signs, risk factors, and the importance of proactive eye care. Curry will share his personal experience living with keratoconus, participate in an educational community event with students in Oakland, and help introduce a Glaukos-authored picture book inspired by his journey. The initiative emphasizes outreach to children, young people, and underserved communities and offers ongoing educational resources via CoulditbeKC.com.
Glaukos (NYSE:GKOS) announced that its management will participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation, where applicable, will be available in the Investors section of the Glaukos website.
Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year-over-year (49% constant currency), with glaucoma net sales of $155.2 million and U.S. glaucoma sales of $118.5 million, up 64% year-over-year. GAAP gross margin was approximately 82% and non-GAAP gross margin approximately 85%.
GAAP loss from operations was $17.3 million and GAAP net loss $18.4 million or ($0.31) per share, while non-GAAP net loss was $8.3 million or ($0.14) per share, including a $1.5 million acquired IPR&D charge. Glaukos ended Q2 2026 with about $289.3 million in cash, equivalents, short-term investments and restricted cash, and no debt, and raised its 2026 net sales guidance to $680–$700 million from $620–$635 million.
Glaukos (NYSE:GKOS) announced completion of patient enrollment in its U.S. 510(k) pivotal study of the PRESERFLO MicroShunt for adult patients with primary open-angle glaucoma who have failed prior medical and surgical treatments. The ab-externo glaucoma drainage device is made from a proprietary SIBS material and designed to lower intraocular pressure (IOP) via a minimally invasive procedure.
The prospective, multi-center, single-arm trial enrolled at least 110 patients across sites in the United States and Canada. The primary effectiveness endpoint is a ≥20% reduction in mean diurnal IOP at 12 months without increasing IOP-lowering medication classes. Glaukos plans to use the results to support a future FDA marketing submission and holds exclusive development and commercialization rights for several markets, including the U.S., Canada, Australia, Brazil, Mexico and New Zealand.
Glaukos (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, plans to release its second quarter 2026 financial results after the market close on Wednesday, July 29, 2026.
Management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET), with access via the investor website and phone dial-in.
Glaukos (NYSE:GKOS) completed patient enrollment in its Phase 2 trial of GLK-321 for Demodex blepharitis. GLK-321 uses the proprietary iLution cream-based eyelid drug-delivery platform with physostigmine as the active ingredient.
The U.S. study randomized 275 patients; the primary endpoint is collarette elimination after six weeks.